Correlation Between Karyopharm Therapeutics and Virax Biolabs

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Virax Biolabs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Virax Biolabs into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Virax Biolabs Group, you can compare the effects of market volatilities on Karyopharm Therapeutics and Virax Biolabs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Virax Biolabs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Virax Biolabs.

Diversification Opportunities for Karyopharm Therapeutics and Virax Biolabs

0.15

Correlation Coefficient

Karyopharm Therapeutics  Virax Biolabs

Average diversification

The 3 months correlation between Karyopharm and Virax is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Virax Biolabs Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virax Biolabs Group and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Virax Biolabs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virax Biolabs Group has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Virax Biolabs go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Virax Biolabs

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Virax Biolabs. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 4.48 times less risky than Virax Biolabs. The stock trades about -0.65 of its potential returns per unit of risk. The Virax Biolabs Group is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  211.00  in Virax Biolabs Group on September 25, 2024 and sell it today you would lose (39.00) from holding Virax Biolabs Group or give up 18.48% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Virax Biolabs Group

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Virax Biolabs Group

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Virax Biolabs Group are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Virax Biolabs showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Karyopharm Therapeutics and Virax Biolabs

The main advantage of trading using opposite Karyopharm Therapeutics and Virax Biolabs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Virax Biolabs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virax Biolabs will offset losses from the drop in Virax Biolabs' long position.

The idea behind Karyopharm Therapeutics and Virax Biolabs Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.